Mildronate, ampoules 10%, 5ml, 10pcs

Composition

>

1 ml of the solution contains:

• active ingredient-meldonium dihydrate 100 mg;
• auxiliary substance-water for injection.

Pharmacological action

of Mildronate-cardioprotective, antihypoxic, angioprotective, antianginal.

Under conditions of increased stress, Mildronate restores the balance between the delivery and demand of cells for oxygen, eliminates the accumulation of toxic metabolic products in cells, protecting them from damage; it has a tonic effect.

As a result of its application, the body acquires the ability to withstand the load and quickly restore energy reserves. Thanks to these properties, Mildronate is used to treat various disorders of the cardiovascular system, blood supply to the brain, as well as to increase physical and mental performance.

As a result of a decrease in the carnitine concentration, gamma-butyrobetaine, which has vasodilating properties, is intensively synthesized. In the case of acute ischemic myocardial injury, Mildronate slows down the formation of a necrotic zone, shortens the rehabilitation period. In heart failure, it increases myocardial contractility, increases exercise tolerance, and reduces the frequency of angina attacks.

In acute and chronic ischemic disorders of the cerebral circulation, it improves blood circulation in the focus of ischemia, promotes blood redistribution in favor of the ischemic area. It is effective in the case of vascular and dystrophic fundus pathology. The drug eliminates functional disorders of the central nervous system in patients with chronic alcoholism and withdrawal symptoms.

Pharmacokinetics

When taken orally, it is well absorbed. Bioavailability is about 78%. _Cmax is reached in 1-2 hours. Biotransformed in the body with the formation of two main metabolites that are excreted by the kidneys. T_1/2 — 3-6 hours and depends on the dose.

Indications

• : hemophthalmos and retinal hemorrhages of various etiologies;
• thrombosis of the central retinal vein and its branches;
• retinopathy of various etiologies (diabetic, hypertensive).

Use during pregnancy and lactation

The safety of using Mildronate during pregnancy has not been proven.

To avoid possible adverse effects on the fetus, the drug should not be prescribed during pregnancy.

It is not known whether the drug is excreted in breast milk.

If it is necessary to use Mildronate during lactation, breastfeeding should be discontinued.

Contraindications

Hypersensitivity; increased intracranial pressure (with impaired venous outflow, intracranial tumors).

Side effects

From the cardiovascular system:  rarely-tachycardia, changes in blood pressure.

From the central nervous system:  rarely-psychomotor agitation.

From the digestive system:  rarely-dyspeptic symptoms.

Allergic reactions:  rarely – skin itching, redness, rash, swelling.

Interaction

When used together, Mildronate enhances the effect of antianginal agents, some antihypertensive drugs, and cardiac glycosides.

Mildronate can be combined with antianginal agents, anticoagulants and antiplatelet agents, antiarrhythmic agents, diuretics, and bronchodilators.

When combined with Mildronate nitroglycerin, nifedipine, alpha-blockers, antihypertensive agents and peripheral vasodilators, moderate tachycardia and arterial hypotension may develop (caution should be exercised when using this combination).

How to take, course of use and dosage

Due to the possibility of developing an excitatory effect, the drug is recommended to be used in the first half of the day.

In case of cardiovascular diseases as part of complex therapy, the drug is prescribed at a dose of 0.5-1 g/day intravenously (5-10 ml of a solution for injection with a concentration of 500 mg/5 ml), the frequency of application is 1-2 times/day. The course of treatment is 4-6 weeks.

If the cerebral circulation is disturbed in the acute phase, the drug is prescribed intravenously at 500 mg 1 time/day for 10 days, then the drug is taken orally (in the appropriate dosage form – 0.5-1 g/day). The general course of therapy is 4-6 weeks.

In vascular pathology and retinal dystrophic diseases, Mildronate is administered parabulbarically in 0.5 ml of a solution for injection with a concentration of 500 mg/5 ml for 10 days.

For mental and physical exertion, IV 500 mg is prescribed 1 time/day. The course of treatment is 10-14 days. If necessary, the therapy is repeated after 2-3 weeks.

In chronic alcoholism, the drug is prescribed intravenously at 500 mg 2 times a day. The course of treatment is 7-10 days.

Overdose

Cases of overdose of Mildronate are not described, the drug is low-toxic and does not cause side effects that are dangerous to the health of patients

Special instructions

The drug is used with caution for a long time in patients with chronic liver and kidney diseases.

Long-term experience in the treatment of acute myocardial infarction and unstable angina in cardiology departments shows that Mildronate is not a first-line drug for acute coronary syndrome.

Influence on the ability to drive motor vehicles and manage mechanisms

There are no data on the adverse effects of Mildronate on the speed of psychomotor response.

Form of production

The solution for injection is clear, colorless.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

4 years

Active ingredient

Meldonium

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection

Description

For adults as directed by your doctor

Indications

Myocardial infarction, Vascular diseases of the eyes, Cerebral circulation disorders, Alcoholism, Hangover, Diabetic Retinopathy, Consequences of stroke, Angina Pectoris, Heart failure